Exploring Spinal Cord Tumors: Causes, Symptoms, and Best Treatment Centers — Overview, Diagnosis & Treatment Options | MyMedicPlus

Spinal cord tumours are classified by their anatomical relationship to the spinal cord and its investing membranes into three major categories. Intramedullary tumours arise within the substance of the spinal cord itself and include spinal ependymoma (the most common intramedullary tumour in adults), spinal astrocytoma (including the diffuse midline glioma H3 K27M-mutant in children and young adults), and haemangioblastoma. Intradural-extramedullary tumours arise within the dural sac but external to the cord and include spinal meningioma, schwannoma (arising from dorsal sensory nerve roots), and neurofibroma. Extradural tumours — the most common category overall — are predominantly metastatic, arising from breast, lung, prostate, renal cell carcinoma, multiple myeloma, and lymphoma. Primary spinal cord tumours account for approximately 2-4% of all central nervous system tumours, with an incidence of approximately 1-2 per 100,000 per year. The cervical and thoracic spine are most commonly affected. Surgical management at specialist neurosurgical centres with intraoperative neurophysiological monitoring is essential for primary spinal tumours.

Most primary spinal cord tumours are sporadic with no identifiable environmental cause. Several hereditary predisposition syndromes are well characterised. Neurofibromatosis type 2 (NF2), caused by NF2 gene mutations on chromosome 22q, predisposes to bilateral vestibular schwannomas as well as multiple spinal meningiomas, schwannomas, and ependymomas. Neurofibromatosis type 1 (NF1) predisposes to plexiform neurofibromas and malignant peripheral nerve sheath tumours (MPNST) of the spinal nerve roots. Von Hippel-Lindau (VHL) syndrome causes spinal and cerebellar haemangioblastomas. Gorlin syndrome (PTCH1 mutations) is associated with a modestly elevated CNS tumour risk. Diffuse midline gliomas of the spinal cord in children frequently harbour H3 K27M mutations (previously associated with DIPG), conferring WHO Grade 4 designation regardless of histological appearance. The most common cause of spinal cord compression overall, however, is metastatic epidural disease from systemic solid tumours or haematological malignancies, which represents a medical and surgical urgency requiring immediate evaluation and treatment.

The clinical presentation of spinal cord tumours reflects the level and extent of cord or nerve root involvement. Progressive myelopathy is the hallmark of intramedullary and large extramedullary tumours: upper motor neuron signs including spasticity, lower extremity hyperreflexia, clonus, and extensor plantar responses (Babinski sign) develop insidiously. A sensory level — a band of altered or absent sensation at the level of cord compression — is a critical clinical finding indicating which vertebral level is involved. Bladder and bowel dysfunction ranging from urgency and frequency to frank urinary retention and constipation indicate significant cord compression. Radicular pain following a dermatomal distribution, often described as burning, shooting, or electric-shock-like, is characteristic of nerve root compression by schwannomas, meningiomas, or foraminal metastases. Cauda equina syndrome from lumbosacral lesions produces a specific constellation: saddle anaesthesia (perineal and perianal numbness), acute urinary retention with overflow incontinence, faecal incontinence, and bilateral leg weakness — this is a neurosurgical emergency requiring decompression within 24-48 hours to prevent permanent neurological deficits.

MRI of the entire spine with gadolinium contrast is the gold standard diagnostic and planning investigation for all suspected spinal cord tumours. MRI provides exquisite delineation of intramedullary versus extramedullary location, cord signal change, extent of epidural compression, and relationship to vertebral bodies and neural foramina. CT myelography is an alternative if MRI is contraindicated due to pacemaker or metallic implants. CT chest, abdomen, and pelvis and PET/CT are essential for distinguishing primary from metastatic aetiology when the diagnosis is uncertain; known primary cancer greatly favours metastatic epidural disease. Biopsy and histological tissue diagnosis with WHO classification (2021 CNS WHO Classification including molecular markers) are required for primary spinal tumours. Specific molecular markers include NF2 mutations in meningioma, H3 K27M in diffuse midline glioma (now WHO Grade 4), and SMARCE1 in clear-cell meningioma. Cerebrospinal fluid cytology and MRI of the entire neuraxis are needed to evaluate leptomeningeal dissemination in high-grade primary spinal tumours. Intraoperative neurophysiological monitoring (SSEPs and MEPs) is planned preoperatively for all intramedullary cases.

The treatment of spinal cord tumours is tailored to tumour type, anatomical location, WHO grade, and patient neurological status. For spinal ependymoma (WHO Grade 2), gross total resection is the goal and is often curative, achievable in over 90% of cases by experienced neurosurgeons using intraoperative neurophysiological monitoring; adjuvant radiotherapy is reserved for incompletely resected or Grade 3 (anaplastic) tumours. For spinal astrocytomas, the infiltrative growth pattern frequently precludes gross total resection; maximal safe resection with intraoperative monitoring followed by focal radiotherapy (50-54 Gy) is the standard approach; high-grade (Grade 3-4) astrocytomas additionally receive temozolomide chemotherapy. Spinal meningiomas and schwannomas: complete surgical resection is curative in the majority of cases; stereotactic radiosurgery is an alternative for surgically inaccessible or recurrent tumours. For metastatic spinal cord compression (MSCC), the evidence-based treatment algorithm mandates: immediate high-dose dexamethasone (16 mg loading dose), urgent MRI of the entire spine, and surgical decompressive laminectomy with posterior stabilisation within 24-48 hours for appropriate surgical candidates, followed by postoperative conventional radiotherapy (20 Gy in 5 fractions or equivalent), as demonstrated by the Patchell et al. landmark trial. Stereotactic body radiotherapy (SBRT) delivers ablative doses (16-24 Gy in 1-3 fractions) to radioresistant spinal metastases while respecting spinal cord tolerance constraints.

There are no established preventive measures for primary sporadic spinal cord tumours, as their aetiology remains largely unknown. However, structured surveillance for individuals with hereditary predisposition syndromes significantly enables early detection and treatment. Individuals with NF2 should undergo annual MRI of the entire neuraxis to detect schwannomas, meningiomas, and ependymomas at the smallest and most surgically accessible size. VHL syndrome carriers require annual spinal MRI for haemangioblastoma detection. Genetic testing of first-degree relatives of NF2 and VHL patients identifies at-risk individuals who should enter surveillance programmes. For metastatic spinal cord compression — the most common cause of spinal cord compromise — optimal systemic cancer treatment with the goal of controlling the primary disease and bone metastases reduces the likelihood and severity of MSCC. Patients with known bone metastases from breast, prostate, lung, or renal cell carcinoma should be treated with bone-protective agents (bisphosphonates or denosumab) according to ASCO and ESMO guidelines to reduce skeletal-related events including MSCC. Early recognition of prodromal back pain in cancer patients and prompt imaging prevents complete paralysis.

Several neurological symptoms constitute medical or surgical emergencies requiring same-day evaluation. Cauda equina syndrome — characterised by saddle anaesthesia, acute urinary retention, new bowel dysfunction, and bilateral leg weakness — is a neurosurgical emergency requiring MRI and surgical decompression within 24-48 hours to prevent permanent paralysis and incontinence. Cancer patients — particularly those with breast, prostate, lung, renal cell, or multiple myeloma — who develop new back pain that is severe, worsening, nocturnal, or associated with any neurological symptom (leg weakness, sensory change, bladder dysfunction) must be assumed to have metastatic spinal cord compression until proven otherwise and require urgent MRI of the entire spine and immediate corticosteroid therapy. Any progressive weakness, numbness, or tingling in the limbs without a clear traumatic or orthopaedic explanation warrants spinal MRI rather than expectant management. Non-cancer patients with new myelopathic signs — spastic gait, hyperreflexia, sensory level — should be referred urgently to a neurosurgeon. Children with back pain and progressive neurological deterioration should be evaluated for intramedullary tumour.

Spinal ependymoma (Grade 2): 5-year OS exceeds 90% with complete resection. Spinal astrocytoma Grade 2: 5-year OS approximately 60-70%; Grade 3/4: approximately 35-40%. Metastatic spinal cord compression: prognosis depends on primary tumour biology and pre-treatment neurological function. Ambulatory status at presentation is the most important predictor of functional outcome — patients who are ambulant at diagnosis have the highest likelihood of remaining ambulant after treatment. The prognosis for Exploring Spinal Cord Tumors: Causes, Symptoms, and Best Treatment Centers varies depending on severity at diagnosis, the patient's overall health, and how promptly treatment is initiated. With early diagnosis and appropriate management, many patients achieve good outcomes and maintain quality of life. Regular follow-up with healthcare providers is essential to monitor progress, adjust treatment as needed, and detect any complications early. Adherence to prescribed treatments and lifestyle modifications significantly improves long-term prognosis.